We are live on ! Find out more
CORV

Correvio Pharma Corp. Ordinary Shares (Canada)
CORV

Delisted

CORV was delisted on the 26th of May, 2020.

36 hedge funds and large institutions have $65.3M invested in Correvio Pharma Corp. Ordinary Shares (Canada) in 2018 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,200% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 1

150% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 4

50% more funds holding

Funds holding: 2436 (+12)

9% more capital invested

Capital invested by funds: $60M → $65.3M (+$5.31M)

99% less call options, than puts

Call options by funds: $3K | Put options by funds: $273K

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
36
Holders Change
+12
Holders Change %
+50%
% of All Funds
0.82%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
13
Increased
10
Reduced
4
Closed
1
Calls
$3K
Puts
$273K
Net Calls
-$270K
Net Calls Change
-$215K

CORV Hedge Fund Activity: Q3 2018 in Review

36 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) for Q3 2018, worth a combined $65.3M — up 8.9% from $60M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CORV positions and 1 closed out — a net gain of 12 holders — while 10 added to existing stakes and 4 trimmed.

The largest buyer was ARS Investment Partners, opening a new position worth an estimated $1.23M. The largest seller was Stonepine Capital Management, cutting an estimated $4.55M.

  • 36 institutional investors held Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) as of Q3 2018, up from 24 in Q2 2018.
  • Funds reported $65.3M of Correvio Pharma Corp. Ordinary Shares (Canada) stock for Q3 2018, up 8.9% quarter-over-quarter.
  • 13 funds opened new Correvio Pharma Corp. Ordinary Shares (Canada) positions in Q3 2018 and 1 closed out, a net change of +12 holders.
  • The largest Correvio Pharma Corp. Ordinary Shares (Canada) buyer in Q3 2018 was ARS Investment Partners, an estimated $1.23M added.
  • The largest Correvio Pharma Corp. Ordinary Shares (Canada) seller in Q3 2018 was Stonepine Capital Management, an estimated $4.55M sold.

Based on aggregated 13F filings for Q3 2018.